Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials (Q34706721)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

0 references

Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials (English)

1 reference

Europe PubMed Central

4 August 2017

0 references

0 references

Helicobacter pylori

1 reference

based on heuristic

inferred from title

eradication of infectious diseases

1 reference

based on heuristic

inferred from title

author name string

Hui-Lin Tang

1

1 reference

Europe PubMed Central

4 August 2017

Yan Li

2

1 reference

Europe PubMed Central

4 August 2017

Yong-Fang Hu

3

1 reference

Europe PubMed Central

4 August 2017

Hong-Guang Xie

4

1 reference

Europe PubMed Central

4 August 2017

Suo-Di Zhai

5

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

30 April 2013

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

8

1 reference

Europe PubMed Central

4 August 2017

e62162

1 reference

Europe PubMed Central

4 August 2017

4

1 reference

Europe PubMed Central

4 August 2017

copyright license

Creative Commons Attribution 4.0 International

30 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Update on the pharmacogenomics of proton pump inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

CYP2C19 genotype and the PPIs--focus on rabeprazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Review article: pharmacology of esomeprazole and comparisons with omeprazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Helicobacter pylori infection and the development of gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

7 July 2018

Rabeprazole: a pharmacologic and clinical review for acid-related disorders

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Helicobacter pylori induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8, -1 alpha/beta, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and t

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

Interluekin-1 beta genetic polymorphism influences the impact of cytochrome P 2C19 genotype on the cure rate of H. pylori eradication therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

26 October 2018

Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

26 October 2018

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639978

26 October 2018

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062162

21 January 2018

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Helicobacter pylori

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23646118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0062162

1 reference

Europe PubMed Central

4 August 2017

2013PLoSO...862162T

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34706721&oldid=1979140251"